{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T08:41:09Z","timestamp":1778661669464,"version":"3.51.4"},"reference-count":49,"publisher":"International Heart Journal (Japanese Heart Journal)","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Int. Heart J."],"published-print":{"date-parts":[[2019,11,30]]},"DOI":"10.1536\/ihj.19-117","type":"journal-article","created":{"date-parts":[[2019,11,14]],"date-time":"2019-11-14T22:12:59Z","timestamp":1573769579000},"page":"1421-1429","source":"Crossref","is-referenced-by-count":17,"title":["Vildagliptin, a DPP-4 Inhibitor, Attenuates Endothelial Dysfunction and Atherogenesis in Nondiabetic Apolipoprotein E-Deficient Mice"],"prefix":"10.1536","volume":"60","author":[{"given":"Kunduziayi","family":"Aini","sequence":"first","affiliation":[{"name":"Department of Cardiovascular Medicine, Tokushima University Graduate School of Biomedical Sciences"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daiju","family":"Fukuda","sequence":"additional","affiliation":[{"name":"Department of Cardio-Diabetes Medicine, Tokushima University Graduate School of Biomedical Science"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kimie","family":"Tanaka","sequence":"additional","affiliation":[{"name":"Division for Health Service Promotion, The University of Tokyo"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yasutomi","family":"Higashikuni","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, The University of Tokyo"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoichiro","family":"Hirata","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, The University of Tokyo Hospital"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shusuke","family":"Yagi","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Tokushima University Graduate School of Biomedical Sciences"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kenya","family":"Kusunose","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Tokushima University Graduate School of Biomedical Sciences"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hirotsugu","family":"Yamada","sequence":"additional","affiliation":[{"name":"Department of Community Medicine for Cardiology, Tokushima University Graduate School of Biomedical Sciences"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takeshi","family":"Soeki","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Tokushima University Graduate School of Biomedical Sciences"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masataka","family":"Sata","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Tokushima University Graduate School of Biomedical Sciences"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"437","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1. Anagnostis P, Athyros VG, Adamidou F, <i>et al<\/i>. Glucagon-like peptide-1-based therapies and cardiovascular disease: looking beyond glycaemic control. Diabetes Obes Metab 2011; 13: 302-12.","DOI":"10.1111\/j.1463-1326.2010.01345.x"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2. Chrysant SG, Chrysant GS. Clinical implications of cardiovascular preventing pleiotropic effects of dipeptidyl peptidase-4 inhibitors. Am J Cardiol 2012; 109: 1681-5.","DOI":"10.1016\/j.amjcard.2012.01.398"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3. Ishizue N, Niwano S, Niwano H, <i>et al<\/i>. Linagliptin suppresses electrical and structural remodeling in the isoproterenol induced myocardial injury model. Int Heart J 2019; 60: 411-8.","DOI":"10.1536\/ihj.18-226"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4. Takahashi A, Ihara M, Yamazaki S, Asanuma H, Asakura M, Kitakaze M. Impact of either GLP-1 agonists or DPP-4 inhibitors on pathophysiology of heart failure. Int Heart J 2015; 56: 372-6.","DOI":"10.1536\/ihj.15-028"},{"key":"5","doi-asserted-by":"publisher","unstructured":"5. Drucker DJ. Incretin action in the pancreas: potential promise, possible perils, and pathological pitfalls. Diabetes 2013; 62: 3316-23.","DOI":"10.2337\/db13-0822"},{"key":"6","doi-asserted-by":"publisher","unstructured":"6. Ban K, Noyan-Ashraf MH, Hoefer J, Bolz SS, Drucker DJ, Husain M. Cardioprotective and vasodilatory actions of glucagon-like peptide 1 receptor are mediated through both glucagon-like peptide 1 receptor-dependent and -independent pathways. Circulation 2008; 117: 2340-50.","DOI":"10.1161\/CIRCULATIONAHA.107.739938"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7. Ussher JR, Drucker DJ. Cardiovascular actions of incretin-based therapies. Circ Res 2014; 114: 1788-803.","DOI":"10.1161\/CIRCRESAHA.114.301958"},{"key":"8","doi-asserted-by":"publisher","unstructured":"8. Ervinna N, Mita T, Yasunari E, <i>et al<\/i>. Anagliptin, a DPP-4 inhibitor, suppresses proliferation of vascular smooth muscles and monocyte inflammatory reaction and attenuates atherosclerosis in male apo E-deficient mice. Endocrinology 2013; 154: 1260-70.","DOI":"10.1210\/en.2012-1855"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9. Salim HM, Fukuda D, Higashikuni Y, <i>et al<\/i>. Dipeptidyl peptidase-4 inhibitor, linagliptin, ameliorates endothelial dysfunction and atherogenesis in normoglycemic apolipoprotein-E deficient mice. Vascul Pharmacol 2016; 79: 16-23.","DOI":"10.1016\/j.vph.2015.08.011"},{"key":"10","doi-asserted-by":"publisher","unstructured":"10. Shah Z, Kampfrath T, Deiuliis JA, <i>et al<\/i>. Long-term dipeptidyl-peptidase 4 inhibition reduces atherosclerosis and inflammation via effects on monocyte recruitment and chemotaxis. Circulation 2011; 124: 2338-49.","DOI":"10.1161\/CIRCULATIONAHA.111.041418"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11. Terasaki M, Nagashima M, Nohtomi K, <i>et al<\/i>. Preventive effect of dipeptidyl peptidase-4 inhibitor on atherosclerosis is mainly attributable to incretin&apos;s actions in nondiabetic and diabetic apolipoprotein E-null mice. PLOS ONE 2013; 8: e70933.","DOI":"10.1371\/journal.pone.0070933"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12. Terasaki M, Nagashima M, Watanabe T, <i>et al<\/i>. Effects of PKF275-055, a dipeptidyl peptidase-4 inhibitor, on the development of atherosclerotic lesions in apolipoprotein E-null mice. Metabolism 2012; 61: 974-7.","DOI":"10.1016\/j.metabol.2011.11.011"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13. Matsubara J, Sugiyama S, Akiyama E, <i>et al<\/i>. Dipeptidyl peptidase-4 inhibitor, sitagliptin, improves endothelial dysfunction in association with its anti-inflammatory effects in patients with coronary artery disease and uncontrolled diabetes. Circ J 2013; 77: 1337-44.","DOI":"10.1253\/circj.CJ-12-1168"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14. Nakamura K, Oe H, Kihara H, <i>et al<\/i>. DPP-4 inhibitor and alpha-glucosidase inhibitor equally improve endothelial function in patients with type 2 diabetes: EDGE study. Cardiovasc Diabetol 2014; 13: 110.","DOI":"10.1186\/s12933-014-0110-2"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15. Guerci B, Monnier L, Serusclat P, <i>et al<\/i>. Continuous glucose profiles with vildagliptin versus sitagliptin in add-on to metformin: results from the randomized Optima study. Diabetes Metab 2012; 38: 359-66.","DOI":"10.1016\/j.diabet.2012.06.001"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16. Sakamoto M, Nishimura R, Irako T, Tsujino D, Ando K, Utsunomiya K. Comparison of vildagliptin twice daily vs. sitagliptin once daily using continuous glucose monitoring (CGM): crossover pilot study (J-VICTORIA study). Cardiovasc Diabetol 2012; 11: 92.","DOI":"10.1186\/1475-2840-11-92"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17. Ross R. Atherosclerosis--an inflammatory disease. N Engl J Med 1999; 340: 115-26.","DOI":"10.1056\/NEJM199901143400207"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18. Bonetti PO, Lerman LO, Lerman A. Endothelial dysfunction: a marker of atherosclerotic risk. Arterioscler Thromb Vasc Biol 2003; 23: 168-75.","DOI":"10.1161\/01.ATV.0000051384.43104.FC"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19. Nemoto T, Minami Y, Yamaoka-Tojo M, <i>et al<\/i>. Impaired flow-mediated dilation and severity and vulnerability of culprit plaque in patients with coronary artery disease. Int Heart J 2019; 60: 539-45.","DOI":"10.1536\/ihj.18-531"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20. Higashi Y, Noma K, Yoshizumi M, Kihara Y. Endothelial function and oxidative stress in cardiovascular diseases. Circ J 2009; 73: 411-8.","DOI":"10.1253\/circj.CJ-08-1102"},{"key":"21","doi-asserted-by":"crossref","unstructured":"21. Hara T, Fukuda D, Tanaka K, <i>et al<\/i>. Inhibition of activated factor X by Rivaroxaban attenuates neointima formation after wire-mediated vascular injury. Eur J Pharmacol 2018; 820: 222-8.","DOI":"10.1016\/j.ejphar.2017.12.037"},{"key":"22","doi-asserted-by":"publisher","unstructured":"22. Hara T, Fukuda D, Tanaka K, <i>et al<\/i>. Rivaroxaban, a novel oral anticoagulant, attenuates atherosclerotic plaque progression and destabilization in ApoE-deficient mice. Atherosclerosis 2015; 242: 639-46.","DOI":"10.1016\/j.atherosclerosis.2015.03.023"},{"key":"23","doi-asserted-by":"crossref","unstructured":"23. Gaspari T, Welungoda I, Widdop RE, Simpson RW, Dear AE. The GLP-1 receptor agonist liraglutide inhibits progression of vascular disease via effects on atherogenesis, plaque stability and endothelial function in an ApoE (\u2212\/\u2212) mouse model. Diab Vasc Dis Res 2013; 10: 353-60.","DOI":"10.1177\/1479164113481817"},{"key":"24","doi-asserted-by":"crossref","unstructured":"24. Salim HM, Fukuda D, Higashikuni Y, <i>et al<\/i>. Teneligliptin, a dipeptidyl peptidase-4 inhibitor, attenuated pro-inflammatory phenotype of perivascular adipose tissue and inhibited atherogenesis in normoglycemic apolipoprotein-E-deficient mice. Vascul Pharmacol 2017; 96-98: 19-25.","DOI":"10.1016\/j.vph.2017.03.003"},{"key":"25","doi-asserted-by":"crossref","unstructured":"25. Michelsen KS, Wong MH, Shah PK, <i>et al<\/i>. Lack of toll-like receptor 4 or myeloid differentiation factor 88 reduces atherosclerosis and alters plaque phenotype in mice deficient in apolipoprotein E. Proc Natl Acad Sci U S A 2004; 101: 10679-84.","DOI":"10.1073\/pnas.0403249101"},{"key":"26","doi-asserted-by":"crossref","unstructured":"26. Ta NN, Schuyler CA, Li Y, Lopes-Virella MF, Huang Y. DPP-4 (CD26) inhibitor alogliptin inhibits atherosclerosis in diabetic apolipoprotein E-deficient mice. J Cardiovasc Pharmacol 2011; 58: 157-66.","DOI":"10.1097\/FJC.0b013e31821e5626"},{"key":"27","doi-asserted-by":"crossref","unstructured":"27. van Poppel PC, Netea MG, Smits P, Tack CJ. Vildagliptin improves endothelium-dependent vasodilatation in type 2 diabetes. Diabetes Care 2011; 34: 2072-7.","DOI":"10.2337\/dc10-2421"},{"key":"28","doi-asserted-by":"crossref","unstructured":"28. Dai Y, Wang X, Ding Z, Dai D, Mehta JL. DPP-4 inhibitors repress foam cell formation by inhibiting scavenger receptors through protein kinase C pathway. Acta Diabetol 2014; 51: 471-8.","DOI":"10.1007\/s00592-013-0541-3"},{"key":"29","doi-asserted-by":"crossref","unstructured":"29. Hirata Y, Kurobe H, Nishio C, <i>et al<\/i>. Exendin-4, a glucagon-like peptide-1 receptor agonist, attenuates neointimal hyperplasia after vascular injury. Eur J Pharmacol 2013; 699: 106-11.","DOI":"10.1016\/j.ejphar.2012.11.057"},{"key":"30","doi-asserted-by":"crossref","unstructured":"30. Matheeussen V, Waumans Y, Martinet W, <i>et al<\/i>. Dipeptidyl peptidases in atherosclerosis: expression and role in macrophage differentiation, activation and apoptosis. Basic Res Cardiol 2013; 108: 350.","DOI":"10.1007\/s00395-013-0350-4"},{"key":"31","doi-asserted-by":"crossref","unstructured":"31. Vanhoutte PM. Endothelial dysfunction: the first step toward coronary arteriosclerosis. Circ J 2009; 73: 595-601.","DOI":"10.1253\/circj.CJ-08-1169"},{"key":"32","first-page":"III27","volume":"109","year":"2004","unstructured":"32. Davignon J, Ganz P. Role of endothelial dysfunction in atherosclerosis. Circulation 2004; 109: III27-32.","journal-title":"Circulation","ISSN":"https:\/\/id.crossref.org\/issn\/0009-7322","issn-type":"print"},{"key":"33","doi-asserted-by":"crossref","unstructured":"33. Gimbrone MA Jr, Garc\u00eda-Carde\u00f1a G. Endothelial cell dysfunction and the pathobiology of atherosclerosis. Circ Res 2016; 118: 620-36.","DOI":"10.1161\/CIRCRESAHA.115.306301"},{"key":"34","doi-asserted-by":"crossref","unstructured":"34. Mason RP, Jacob RF, Kubant R, <i>et al<\/i>. Effect of enhanced glycemic control with saxagliptin on endothelial nitric oxide release and CD40 levels in obese rats. J Atheroscler Thromb 2011; 18: 774-83.","DOI":"10.5551\/jat.7666"},{"key":"35","doi-asserted-by":"crossref","unstructured":"35. Ishii M, Shibata R, Kondo K, <i>et al<\/i>. Vildagliptin stimulates endothelial cell network formation and ischemia-induced revascularization via an endothelial nitric-oxide synthase-dependent mechanism. J Biol Chem 2014; 289: 27235-45.","DOI":"10.1074\/jbc.M114.557835"},{"key":"36","doi-asserted-by":"crossref","unstructured":"36. Kim HJ, Baek EB, Kim SJ. Potentiation of endothelium-dependent vasorelaxation of mesenteric arteries from spontaneously hypertensive rats by gemigliptin, a dipeptidyl peptidase-4 inhibitor class of anti-diabetic drug. Korean J Physiol Pharmacol 2018; 22: 713-9.","DOI":"10.4196\/kjpp.2018.22.6.713"},{"key":"37","doi-asserted-by":"crossref","unstructured":"37. Shah Z, Pineda C, Kampfrath T, <i>et al<\/i>. Acute DPP-4 inhibition modulates vascular tone through GLP-1 independent pathways. Vascul Pharmacol 2011; 55: 2-9.","DOI":"10.1016\/j.vph.2011.03.001"},{"key":"38","doi-asserted-by":"crossref","unstructured":"38. Ceriello A, Novials A, Ortega E, <i>et al<\/i>. Glucagon-like peptide 1 reduces endothelial dysfunction, inflammation, and oxidative stress induced by both hyperglycemia and hypoglycemia in type 1 diabetes. Diabetes Care 2013; 36: 2346-50.","DOI":"10.2337\/dc12-2469"},{"key":"39","doi-asserted-by":"crossref","unstructured":"39. Erdogdu \u00d6, Eriksson L, Nystr\u00f6m T, Sj\u00f6holm \u00c5, Zhang Q. Exendin-4 restores glucolipotoxicity-induced gene expression in human coronary artery endothelial cells. Biochem Biophys Res Commun 2012; 419: 790-5.","DOI":"10.1016\/j.bbrc.2012.02.106"},{"key":"40","doi-asserted-by":"publisher","unstructured":"40. Wu L, Liu X, Wang L, <i>et al<\/i>. Exendin-4 protects HUVECs from tunicamycin-induced apoptosis via inhibiting the IRE1a\/JNK\/caspase-3 pathway. Endocrine 2017; 55: 764-72.","DOI":"10.1007\/s12020-016-1190-4"},{"key":"41","doi-asserted-by":"crossref","unstructured":"41. Colasanti M, Persichini T, Cavalieri E, <i>et al<\/i>. Rapid inactivation of NOS-I by lipopolysaccharide plus interferon-gamma-induced tyrosine phosphorylation. J Biol Chem 1999; 274: 9915-7.","DOI":"10.1074\/jbc.274.15.9915"},{"key":"42","doi-asserted-by":"crossref","unstructured":"42. Kamoun WS, Karaa A, Kresge N, Merkel SM, Korneszczuk K, Clemens MG. LPS inhibits endothelin-1-induced endothelial NOS activation in hepatic sinusoidal cells through a negative feedback involving caveolin-1. Hepatology 2006; 43: 182-90.","DOI":"10.1002\/hep.20940"},{"key":"43","doi-asserted-by":"crossref","unstructured":"43. Ding J, Song D, Ye X, Liu SF. A pivotal role of endothelial-specific NF-kappaB signaling in the pathogenesis of septic shock and septic vascular dysfunction. J Immunol 2009; 183: 4031-8.","DOI":"10.4049\/jimmunol.0900105"},{"key":"44","doi-asserted-by":"crossref","unstructured":"44. Stark RJ, Koch SR, Choi H, <i>et al<\/i>. Endothelial nitric oxide synthase modulates toll-like receptor 4-mediated IL-6 production and permeability via nitric oxide-independent signaling. FASEB J 2018; 32: 945-56.","DOI":"10.1096\/fj.201700410R"},{"key":"45","doi-asserted-by":"crossref","unstructured":"45. Erdogdu O, Eriksson L, Xu H, Sj\u00f6holm A, Zhang Q, Nystr\u00f6m T. Exendin-4 protects endothelial cells from lipoapoptosis by PKA, PI3K, eNOS, p38 MAPK, and JNK pathways. J Mol Endocrinol 2013; 50: 229-41.","DOI":"10.1530\/JME-12-0166"},{"key":"46","doi-asserted-by":"crossref","unstructured":"46. Han L, Yu Y, Sun X, Wang B. Exendin-4 directly improves endothelial dysfunction in isolated aortas from obese rats through the cAMP or AMPK-eNOS pathways. Diabetes Res Clin Pract 2012; 97: 453-60.","DOI":"10.1016\/j.diabres.2012.04.001"},{"key":"47","doi-asserted-by":"crossref","unstructured":"47. Iwaya C, Nomiyama T, Komatsu S, <i>et al<\/i>. Exendin-4, a glucagonlike peptide-1 receptor agonist, attenuates breast cancer growth by inhibiting NF-\u03baB activation. Endocrinology 2017; 158: 4218-32.","DOI":"10.1210\/en.2017-00461"},{"key":"48","doi-asserted-by":"crossref","unstructured":"48. Krasner NM, Ido Y, Ruderman NB, Cacicedo JM. Glucagon-like peptide-1 (GLP-1) analog liraglutide inhibits endothelial cell inflammation through a calcium and AMPK dependent mechanism. PLOS ONE 2014; 9: e97554.","DOI":"10.1371\/journal.pone.0097554"},{"key":"49","doi-asserted-by":"crossref","unstructured":"49. Steven S, Hausding M, Kr\u00f6ller-Sch\u00f6n S, <i>et al<\/i>. Gliptin and GLP-1 analog treatment improves survival and vascular inflammation\/dysfunction in animals with lipopolysaccharide-induced endotoxemia. Basic Res Cardiol 2015; 110: 6.","DOI":"10.1007\/s00395-015-0465-x"}],"container-title":["International Heart Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/ihj\/60\/6\/60_19-117\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,12,2]],"date-time":"2019-12-02T10:50:46Z","timestamp":1575283846000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/ihj\/60\/6\/60_19-117\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,11,30]]},"references-count":49,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2019]]}},"URL":"https:\/\/doi.org\/10.1536\/ihj.19-117","relation":{},"ISSN":["1349-2365","1349-3299"],"issn-type":[{"value":"1349-2365","type":"print"},{"value":"1349-3299","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,11,30]]}}}